Molecular Formula | C21H27N7O
|
Molar Mass | 393.49 |
Density | 1.343±0.06 g/cm3(Predicted) |
Melting Point | 305℃ (decomposition) |
Boling Point | 736.4±70.0 °C(Predicted) |
Solubility | DMSO: soluble7 mg/mL;H2O: insoluble |
Appearance | solid |
Color | Off-white |
pKa | 10.51±0.10(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months |
MDL | MFCD07784513 |
Use | Reversine is a synthetic purine analog that can inhibit Aurora A/B/C with IC50 of 150 to 500 nM. |
In vitro study | Reversine induces myogenic lineage-committed cells to become multipotent mesenchymal progenitor cells, which proliferates and redifferentiates into bone and fat cells. Reversine, as an A3 adenosine receptor antagonist, competitively inhibits forskolin-stimulated cAMP production in stably transfected Chinese hamster ovary (CHO) cells. Reversine inhibits the phosphorylation of a well-known Aurora target, histone H3 in HCT116 cells. Moreover, Reversine potently blocks proliferation of multiple tumor cell types, and induces cell death. In primary human tumor samples, Reversine also inhibits colony formation of leukemic cells. When treated in combination, reversine and aspirin synergistically inhibit growth of cervical cancer cells and induce cell apoptosis. |
In vivo study | In mice inoculated with U14 tumors, Reversine (10 mg/kg i.p.) and aspirin cause more reduced tumor weight and tumor volume when compared with the control agents. |